ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,682Medicare Part D Prescriptions Filled, Including Refills

Rank: 5 out of 16

$540K Total Retail Price of All Prescriptions

Rank: 5 out of 16

425 Patients Receiving at Least One Drug in Part D
82%Patients 65 Years and Older
27% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 425 patients filled at least one prescription for a schedule two drug, compared to an average of 11%.

Schedule Three
Controlled Substances

7% of this provider’s 425 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 9,623 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $44 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 35.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
OMEPRAZOLE 576 476 1 5
SIMVASTATIN 556 442 2 2
AMLODIPINE BESYLATE 495 452 3 7
LEVOTHYROXINE SODIUM 456 368 4 6
FUROSEMIDE 381 337 5 3
LISINOPRIL 327 301 6 4
WARFARIN SODIUM 324 324 7 1
ATENOLOL 256 227 8 17
CITALOPRAM HBR 243 212 9 12
HYDROCHLOROTHIAZIDE 235 205 10 14
DONEPEZIL HCL 220 195 11 9
HYDROCODONE-ACETAMINOPHEN 185 159 S3 12 15
ATORVASTATIN CALCIUM 179 140 13 13
METOPROLOL TARTRATE 177 131 14 8
TAMSULOSIN HCL 169 145 15 21
TRIAMTERENE-HCTZ 169 169 15 75
PREDNISONE 166 153 17 40
TRAZODONE HCL 156 125 18 11
GABAPENTIN 144 116 19 19
RANITIDINE HCL 134 113 20 51
METOPROLOL SUCCINATE 126 126 21 23
POLYETHYLENE GLYCOL 3350 122 75 22 24
MIRTAZAPINE 122 122 22 16
NAMENDA 118 118 24 18
SERTRALINE HCL 117 91 25 10
METFORMIN HCL 109 73 26 20
ALENDRONATE SODIUM 105 104 27 25
ALLOPURINOL 97 85 28 29
CYMBALTA 95 63 29 33
PANTOPRAZOLE SODIUM 94 94 30 32
DIOVAN 91 79 31 30
KLOR-CON M20 87 75 32 46
POTASSIUM CHLORIDE 84 71 33 43
LOSARTAN POTASSIUM 84 76 33 27
FLUOXETINE HCL 81 61 35 93
CRESTOR 78 78 36 50
ZOLPIDEM TARTRATE 78 60 36 41
FLUTICASONE PROPIONATE 75 58 38 58
NEXIUM 73 55 39 78
JANUVIA 65 47 40 119
SPIRIVA 65 53 40 31
MELOXICAM 62 56 42 67
PROAIR HFA 59 21 43 73
IBUPROFEN 58 33 44 78
DEXILANT 58 33 44 167
VENLAFAXINE HCL ER 57 37 46 49
SINGULAIR 57 27 46 92
DILTIAZEM 24HR ER 57 57 46 80
ISOSORBIDE MONONITRATE ER 52 52 49 48
LISINOPRIL-HYDROCHLOROTHIAZIDE 51 39 50 81
EVISTA 51 51 50 184
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 24, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.